| Species |
Human |
| Protein Construction |
| Flag |
His |
TRAIL Trimer (Gly118-Gly281)_x000D_
Accession # P50591-1 |
| N-term |
|
C-term |
|
| Purity |
> 95% as determined by BisTris PAGE
> 90% as determined by HPLC |
| Endotoxin Level |
Less than 1 EU per μg by the LAL method. |
| Biological Activity |
Measured by its binding ability in a functional ELISA. Immobilized TRAIL Trimer, His & Flag, Human at 2μg/ml (100μl/well) on the plate can bind Human TRAIL R1, hFc Tag. Test result was comparable to standard batch. |
| Expression System |
HEK293 |
| Theoretical Molecular Weight |
60 kDa |
| Apparent Molecular Weight |
Due to glycosylation, the protein migrates to 55-65 kDa based on Bis-Tris PAGE result. |
| Formulation |
Lyophilized from 0.22 μm filtered solution in PBS (pH 7.4). |
| Reconstitution |
Centrifuge the tube before opening. Reconstituting to a concentration more than 100 μg/ml is recommended. Dissolve the lyophilized protein in distilled water. |
| Storage & Stability |
Upon receiving, the product remains stable up to 6 months at -20 °C or below. Upon reconstitution, the product should be stable for 3 months at -80 °C. Avoid repeated freeze-thaw cycles. |
| Target Background |
Tumor necrosis factor (TNF)-related apoptosis-inducing ligand (TRAIL) is a member of the TNF superfamily that can initiate the apoptosis pathway by binding to its associated death receptors DR4 and DR5. The activation of the TRAIL pathway in inducing tumor-selective apoptosis leads to the development of TRAIL-based cancer therapies, which include recombinant forms of TRAIL, TRAIL receptor agonists, and other therapeutic agents. |
| Synonyms |
Apo-2L; TRAIL; CD253; TNFSF10; Apo-2 ligand; APO2L; TL2 |
For research use only. Not intended for human or animal clinical trials, therapeutic or diagnostic use.
